E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
We investigate the PaO2/FiO2 ratio in patients without and with mild to moderate ARDS |
We onderzoeken de PaO2/FiO2 ratio in patienten met en zonder mild tot matige ARDS |
|
E.1.1.1 | Medical condition in easily understood language |
We investigate the effect of inspired oxygen fraction on PaO2/FiO2 ratio as estimate of lung injury |
We onderzoeken het effect van de toegediende zuurstof fractie op PaO2/FiO2 ratio als maat voor longschade |
|
E.1.1.2 | Therapeutic area | Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Diagnosis [E01] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.0 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10003083 |
E.1.2 | Term | ARDS |
E.1.2 | System Organ Class | 100000004855 |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To study the effect of FiO2 on the PaO2/FiO2-ratio in mechanically ventilated patients post cardiac surgery without ARDS and with mild to moderate ARDS |
Het onderzoeken van het effect van FiO2 op de PaO2/FiO2-ratio in beademde patienten na cardiochirurgie zonder en met milde tot matige ARDS |
|
E.2.2 | Secondary objectives of the trial |
Shunt fraction, arteriovenous oxygen difference and alveolar – arterial oxygen difference |
Shunt fractie, arterioveneuze en alveolaire – arteriele zuurstofverschil |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
All mechanically ventilated patients, admitted to the Intensive Care Unit of VU-Medical Center post cardiac surgery without ARDS and with mild to moderate ARDS will be screened for eligibility for this study. In order to be eligible to participate in this study, a subject must meet all of the following criteria:
• Mechanically ventilated patients • Stable hemodynamics • Stable haemoglobin level • Stable body temperature • Stable level of sedation • Pulmonary-Artery and Artery catheter
|
Alle beademde patienten, opgenomen op de Intensive Care van het VU Medisch centrum na cardiochirurgie zonder en met milde tot matige ARDS. Een patient moet aan de volgende criteria voldoen:
• Beademde patienten • Stabiele hemodynamiek • Stabiele hemoglobine concentratie • Stabiele lichaams temperatuur • Stabiel sedatie niveau • Swan Ganz catheter en arterielijn
|
|
E.4 | Principal exclusion criteria |
• Incomplete revascularization after CABG • Cardiac ischemia • Neurotrauma
|
• Incomplete revascularizatie na CABG • Cardiale ischemie • Neurotrauma
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
The relationship between FiO2 and PaO2/FiO2-ratio |
De relatie tussen FiO2 en PaO2/FiO2-ratio |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
Every 10 minutes after the start of the protocol |
Elke 10 minuten na de start van het protocol |
|
E.5.2 | Secondary end point(s) |
Shunt fraction, arteriovenous oxygen difference and alveolar – arterial oxygen difference |
Shunt fractie, arterioveneuze en alveolaire – arteriele zuurstof verschil |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
Every 10 minutes after the start of the protocol |
Elke 10 minuten na de start van het protocol |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | Yes |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | No |
E.6.5 | Efficacy | No |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | Yes |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | No |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | Yes |
E.8.2.3.1 | Comparator description |
De PaO2/FiO2 ratio van patienten zonderARDS wordt vergeleken met patienten met mild tot matige ARDS |
The PaO2/FiO2 ratio will be compared of patients without ARDS and mild to moderate ARDS |
|
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| Yes |
E.8.4 | The trial involves multiple sites in the Member State concerned | No |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
When the last patient has completed the protocol at the ICU. |
Als de laatste patient het protocol voltooid heeft op de Intensive Care. |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 1 |
E.8.9.1 | In the Member State concerned months | |
E.8.9.1 | In the Member State concerned days | |